Deaminase Modulation Driving a New Era in Drug Development

Our expanding understanding of the complex roles of endogenous mutagenic deaminases in human disease is driving the development of a new generation of therapeutics. These emerging drugs aim to achieve clinical benefit by modulating deaminase activity. Because these enzymes are intrinsic to key inflammation-related pathways, they represent promising targets for future therapeutic innovation. Although only a small number of deaminase-modulating agents have been approved for clinical use, many more are currently under investigation. Here, we present examples that illustrate the therapeutic potential of modulating this diverse family of enzymes and identify some of the challenges and opportunities that warrant further exploration.